Skip to main content
Erschienen in:

01.08.2008

Antiapoptosis and Mitochondrial Effect of Pioglitazone Preconditioning in the Ischemic/reperfused Heart of Rat

verfasst von: Jian Li, Ming-Jian Lang, Xiao-Bo Mao, Li Tian, Yi-Bai Feng

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Pioglitazone, used clinically in the treatment of type 2 diabetes mellitus, has been implicated as a regulator of cellular inflammatory and ischemic responses. The present study examined whether pioglitazone could inhibit cadiocyte apoptosis and reduce mitochondrial ultrastructure injury and membrane potential loss in the ischemic/reperfused heart of the rat. Furthermore, we investigated whether the protective effect of pioglitazone was related to opening of the mitochondrialATP-sensitive potassium channels.

Methods

Adult male Sprague–Dawley rats were subjected to 30 min of ischemia followed by 4 h of reperfusion. At 24 h before ischemia, rats were randomized to receive 0.9% saline, 5-hydroxydecanoate (5-HD, 10 mg kg−1, i.v.) plus pioglitazone (3 mg kg−1, i.v.) or pioglitazone (3 mg kg−1, i.v.). One group served as sham control. We investigated mitochondrial structure, apoptosis rate and Bcl-2, Bax and Caspase-3 proteins by immunohistochemistry staining. RT-PCR was used to determine the expression of P38MAPKmRNA and JNKmRNA. Western blotting was used to measure the expression of P38MAPK, JNK and NFκB P65. A second group of rats were randomly divided into sham-operated, ischemia/reperfusion (I/R), pioglitazone treatment, 5-HD + pioglitazone and 5-HD groups and the size of myocardial infarction was determined. Primary cultured cardiomyocytes of neonatal Sprague–Dawley rats were divided into control, hypoxia reoxygenation, different concentrations of pioglitazone and 5-HD + pioglitazone groups. JC-1 staining flowcytometry was used to examine mitochondrial membrane potential (ΔΨm).

Results

Pioglitazone decreased mitochondrial ultrastructural damage compared to I/R, and reduced infarct size from 34.93 ± 5.55% (I/R) to 20.24 ± 3.93% (P < 0.05). Compared with the I/R group, the apoptosis rate and positive cell index (PCI) of Bax and Caspase-3 proteins in the pioglitazone group were significantly decreased (P < 0.05), while the PCI of Bcl-2 protein was increased (P < 0.05). There was no significant difference between the I/R and 5-HD + pioglitazone groups. Compared with the sham-operated group, the expression of P38MAPK mRNA, JNK mRNA and protein of P38MAPK, JNK and NFκB P65 in I/R was increased (P < 0.05). Pioglitazone did inhibit the increase in expressions vs I/R (P < 0.05). The rate of loss ΔΨm cells in the pioglitazone group was significantly lower than in the hypoxia reoxygenation group, while the addition of 5-HD inhibited the effect of pioglitazone.

Conclusion

Pioglitazone inhibited cadiocyte apoptosis and reduced mitochondrial ultrastructure injury and membrane potential loss in the ischemic/reperfused heart of rat. These protective effects of pioglitazone may be related to opening mitochondrialATP-sensitive potassium channels.
Literatur
1.
Zurück zum Zitat Liu H-R, Gao F, Tao L. Antiapoptotic mechanisms of benidipine in the ischemic/reperfused heart. Br J Pharmacol. 2004;142:627–34.PubMedCrossRef Liu H-R, Gao F, Tao L. Antiapoptotic mechanisms of benidipine in the ischemic/reperfused heart. Br J Pharmacol. 2004;142:627–34.PubMedCrossRef
2.
Zurück zum Zitat Tsutsumi YM, Yokoyama T, Horikawa Y, Roth DM, Patel HH. Reactive oxygen species trigger ischemic and pharmacological postconditioning: in vivo and in vitro characterization. Life Sci. 2007;81:1223–7.PubMedCrossRef Tsutsumi YM, Yokoyama T, Horikawa Y, Roth DM, Patel HH. Reactive oxygen species trigger ischemic and pharmacological postconditioning: in vivo and in vitro characterization. Life Sci. 2007;81:1223–7.PubMedCrossRef
3.
Zurück zum Zitat Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113–51.PubMed Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113–51.PubMed
4.
Zurück zum Zitat Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation. 1993;88:1264–72.PubMed Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation. 1993;88:1264–72.PubMed
5.
Zurück zum Zitat Baxter GF, Goma FM, Yellon DM. Characterisation of the infarct-limiting effect of delayed preconditioning: time course and dose-dependency studies in rabbit myocardium. Basic Res Cardiol. 1997;92:159–67.PubMedCrossRef Baxter GF, Goma FM, Yellon DM. Characterisation of the infarct-limiting effect of delayed preconditioning: time course and dose-dependency studies in rabbit myocardium. Basic Res Cardiol. 1997;92:159–67.PubMedCrossRef
6.
Zurück zum Zitat Grover GJ, Garlid KD. ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol. 2000;32:677–95.PubMedCrossRef Grover GJ, Garlid KD. ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol. 2000;32:677–95.PubMedCrossRef
7.
Zurück zum Zitat Gross GJ, Fryer RM. Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Circ Res. 1999;84:973–9.PubMed Gross GJ, Fryer RM. Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Circ Res. 1999;84:973–9.PubMed
8.
Zurück zum Zitat Mironova GD, Skarga YY, Grigoriev SM, Negoda AE, Kolomytkin OV, Marinov BS. Reconstitution of the mitochondrial ATP-dependent potassium channel into bilayer lipid membrane. J Bioenerg Biomembr. 1999;31:159–63.PubMedCrossRef Mironova GD, Skarga YY, Grigoriev SM, Negoda AE, Kolomytkin OV, Marinov BS. Reconstitution of the mitochondrial ATP-dependent potassium channel into bilayer lipid membrane. J Bioenerg Biomembr. 1999;31:159–63.PubMedCrossRef
9.
Zurück zum Zitat O’Rourke B. Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res. 2004;94:420–32.PubMedCrossRef O’Rourke B. Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res. 2004;94:420–32.PubMedCrossRef
10.
Zurück zum Zitat Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia/reperfusion injury, inflammation and shock. Cardiovasc Res. 2005;65:772–81.PubMedCrossRef Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia/reperfusion injury, inflammation and shock. Cardiovasc Res. 2005;65:772–81.PubMedCrossRef
11.
Zurück zum Zitat Flink IL, Edwards JG, Bahl JJ, et al. Characterization of a strong positive cis-acting element of the human beta-myosin heavy chain gene in fetal rat heart cells. J Biol Chem. 1992;267:9917–24.PubMed Flink IL, Edwards JG, Bahl JJ, et al. Characterization of a strong positive cis-acting element of the human beta-myosin heavy chain gene in fetal rat heart cells. J Biol Chem. 1992;267:9917–24.PubMed
12.
Zurück zum Zitat Yue T-L, Bao W, Gu J-L, et al. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes. 2005;54:554–62.PubMedCrossRef Yue T-L, Bao W, Gu J-L, et al. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes. 2005;54:554–62.PubMedCrossRef
13.
Zurück zum Zitat Li D, Chen K, Sinha N, et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res. 2005;65:907–12.PubMedCrossRef Li D, Chen K, Sinha N, et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res. 2005;65:907–12.PubMedCrossRef
14.
Zurück zum Zitat Regan SE, Brond M, et al. A1 adenosine receptor overexpression attenuates ischemia–reperfusion-induced apoptosis and caspase 3 activity. Am J Physiol Heart Circ Physiol. 2003;284:H859–66.PubMed Regan SE, Brond M, et al. A1 adenosine receptor overexpression attenuates ischemia–reperfusion-induced apoptosis and caspase 3 activity. Am J Physiol Heart Circ Physiol. 2003;284:H859–66.PubMed
15.
Zurück zum Zitat Crow MT, Mani K, et al. The mitochondrial death pathway and cardiac myocyte apoptosis. Circulation Research. 2004;95:957–63.PubMedCrossRef Crow MT, Mani K, et al. The mitochondrial death pathway and cardiac myocyte apoptosis. Circulation Research. 2004;95:957–63.PubMedCrossRef
16.
Zurück zum Zitat Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994;94:1621–8.PubMedCrossRef Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994;94:1621–8.PubMedCrossRef
17.
Zurück zum Zitat Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614–20.PubMedCrossRef Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614–20.PubMedCrossRef
18.
Zurück zum Zitat Grunenfelder J, Miniati DN, Murata S, et al. Upregulation of Bcl-2 through caspase-3 inhibition ameliorates ischemia/reperfusion injury in rat cardiac allografts. Circulation. 2001;104:1-202–6.CrossRef Grunenfelder J, Miniati DN, Murata S, et al. Upregulation of Bcl-2 through caspase-3 inhibition ameliorates ischemia/reperfusion injury in rat cardiac allografts. Circulation. 2001;104:1-202–6.CrossRef
19.
Zurück zum Zitat Nakamura M, Wang NP, Zhao ZQ, Wilcox JN, Thourani VH, Guyton RA, et al. Preconditioning decreases Bax expression, PMN accumulation and apoptosis in reperfused rat heart. Cardiovasc Res. 2002;45:661–70.CrossRef Nakamura M, Wang NP, Zhao ZQ, Wilcox JN, Thourani VH, Guyton RA, et al. Preconditioning decreases Bax expression, PMN accumulation and apoptosis in reperfused rat heart. Cardiovasc Res. 2002;45:661–70.CrossRef
20.
Zurück zum Zitat Piot C, Martini J-F, Bui S, Wolfe CL. Ischemic preconditioning attenuates ischemia/reperfusion-induced activation of caspases and subsequent cleavage of poly (ADP-ribose) polymerase in rat hearts in vivo. Cardiovasc Res. 1999;44:536–42.PubMedCrossRef Piot C, Martini J-F, Bui S, Wolfe CL. Ischemic preconditioning attenuates ischemia/reperfusion-induced activation of caspases and subsequent cleavage of poly (ADP-ribose) polymerase in rat hearts in vivo. Cardiovasc Res. 1999;44:536–42.PubMedCrossRef
21.
Zurück zum Zitat Javadov S, Karmzzyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem. 2007;20:1–22.PubMedCrossRef Javadov S, Karmzzyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem. 2007;20:1–22.PubMedCrossRef
22.
Zurück zum Zitat Bae MA, Song BJ. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol. 2003;63:401–8.PubMedCrossRef Bae MA, Song BJ. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol. 2003;63:401–8.PubMedCrossRef
23.
Zurück zum Zitat Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 2005;120:649–61.PubMedCrossRef Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 2005;120:649–61.PubMedCrossRef
24.
Zurück zum Zitat Schroeter H, Boyd CS, Ahmed R, Spencer JP, Duncan RF, Rice-Evans C, et al. c-Jun N-terminal kinase (JNK)-mediated modulation of brain mitochondria function: new target proteins for JNK signalling in mitochondrion-dependent apoptosis. Biochem J. 2003;372:359–69.PubMedCrossRef Schroeter H, Boyd CS, Ahmed R, Spencer JP, Duncan RF, Rice-Evans C, et al. c-Jun N-terminal kinase (JNK)-mediated modulation of brain mitochondria function: new target proteins for JNK signalling in mitochondrion-dependent apoptosis. Biochem J. 2003;372:359–69.PubMedCrossRef
25.
Zurück zum Zitat Mohit AA, Martin JH, Miller CA. p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron. 1995;14:67–78.PubMedCrossRef Mohit AA, Martin JH, Miller CA. p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron. 1995;14:67–78.PubMedCrossRef
26.
Zurück zum Zitat Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D, et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med. 1996;2:668–75.PubMedCrossRef Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D, et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med. 1996;2:668–75.PubMedCrossRef
27.
28.
Zurück zum Zitat Moolman JA, Hartley S, Van Wyk J, et al. Inhibition of myocardial apoptosis by ischemic and beta-adrenergic preconditioning is dependent on p38 MAPK. Cardiovasc Drugs Ther. 2006;20:13–25.PubMedCrossRef Moolman JA, Hartley S, Van Wyk J, et al. Inhibition of myocardial apoptosis by ischemic and beta-adrenergic preconditioning is dependent on p38 MAPK. Cardiovasc Drugs Ther. 2006;20:13–25.PubMedCrossRef
29.
Zurück zum Zitat Petrich BG, Wang Y. Stress-activated MAP kinases in cardiac remodeling and heart failure: new insights from transgenic studies. Trends Cardiovasc Med. 2004;14:50–5.PubMedCrossRef Petrich BG, Wang Y. Stress-activated MAP kinases in cardiac remodeling and heart failure: new insights from transgenic studies. Trends Cardiovasc Med. 2004;14:50–5.PubMedCrossRef
30.
Zurück zum Zitat Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 1999;99:1685–91.PubMed Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 1999;99:1685–91.PubMed
31.
Zurück zum Zitat He H, Li HL, Lin A, Gottlieb RA. Activation of the JNK pathway is important for cardiomyocyte death in response to simulated ischemia. Cell Death Differ. 1999;6:987–91.PubMedCrossRef He H, Li HL, Lin A, Gottlieb RA. Activation of the JNK pathway is important for cardiomyocyte death in response to simulated ischemia. Cell Death Differ. 1999;6:987–91.PubMedCrossRef
32.
Zurück zum Zitat Andreka P, Zang J, Dougherty C, Slepak TI, Webster KA, Bishopric NH. Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ Res. 2001;88:305–12.PubMed Andreka P, Zang J, Dougherty C, Slepak TI, Webster KA, Bishopric NH. Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ Res. 2001;88:305–12.PubMed
33.
Zurück zum Zitat Hernández Gutiérrez S, Rojas del Castillo E. Role of the transcription factor NF-kappaB in the cardiac cell. Arch Cardiol Mex 2005;75:363–70.PubMed Hernández Gutiérrez S, Rojas del Castillo E. Role of the transcription factor NF-kappaB in the cardiac cell. Arch Cardiol Mex 2005;75:363–70.PubMed
34.
Zurück zum Zitat Shunichi K, Toru K, Yoshiya M, et al. Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291:H1337–44.CrossRef Shunichi K, Toru K, Yoshiya M, et al. Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291:H1337–44.CrossRef
35.
Zurück zum Zitat Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element “decoy” against nuclear factor-kB binding site prevents myocardial infarction. Nat Med. 1997;3:894–9.PubMedCrossRef Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element “decoy” against nuclear factor-kB binding site prevents myocardial infarction. Nat Med. 1997;3:894–9.PubMedCrossRef
36.
Zurück zum Zitat Chandrasekar B, Freeman GL. Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium. FEBS Lett. 1997;401:30–4.PubMedCrossRef Chandrasekar B, Freeman GL. Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium. FEBS Lett. 1997;401:30–4.PubMedCrossRef
Metadaten
Titel
Antiapoptosis and Mitochondrial Effect of Pioglitazone Preconditioning in the Ischemic/reperfused Heart of Rat
verfasst von
Jian Li
Ming-Jian Lang
Xiao-Bo Mao
Li Tian
Yi-Bai Feng
Publikationsdatum
01.08.2008
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 4/2008
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-008-6115-x

Weitere Artikel der Ausgabe 4/2008

Cardiovascular Drugs and Therapy 4/2008 Zur Ausgabe

Neu im Fachgebiet Kardiologie

Aggressive Blutdrucksenkung bei Risikopersonen?

12.07.2024 Arterielle Hypertonie Nachrichten

Geht es nach einer aktuellen chinesischen Studie, ist die Einstellung des systolischen Blutdrucks bei Risikopersonen auf Werte unter 120 mmHg mit weniger kardiovaskulären Ereignissen assoziiert als die Senkung auf Werte unter 140 mmHg.

Mehr Komplikationen beim akuten Koronarsyndrom ohne klassische Risikofaktoren

11.07.2024 Akutes Koronarsyndrom Nachrichten

Ein steigender Anteil von Personen mit akutem Koronarsyndrom (ACS) weist keine modifizierbaren Risikofaktoren auf. Wie sich das auf die Prognose auswirkt, wurde anhand eines australischen PCI-Registers untersucht. 

Taugen Risikoscores für Schlaganfall und Blutungen auch bei Krebskranken?

Britische Registerdaten sprechen dafür, dass sich die Blutungsrisikoprädiktion bei Personen mit Vorhofflimmern, die zugleich an Krebs leiden, nicht einfach aus Kohorten ohne Krebs übertragen lässt.

Bewusstsein während Reanimation – gibt es "typische" Fälle?

10.07.2024 Kardiopulmonale Reanimation Nachrichten

Australische Rettungsdienstdaten deuten darauf hin, dass sich Fälle, in denen eine laufende Reanimation Anzeichen von Bewusstsein induziert, von anderen Wiederbelebungsfällen unterscheiden könnten. Etwa mit Blick auf die Überlebenschancen.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.